|
 |
|
REVIEW ARTICLE |
|
|
|
| Year : 2012 | Volume
: 16
| Issue : 2 | Page : 59-62 |
| |
High altitude pulmonary edema-clinical features, pathophysiology, prevention and treatment
Swapnil J Paralikar
Department of Physiology, GMERS Medical College, Gotri, Vadodara, Gujarat, India
| Date of Web Publication | 13-Feb-2013 |
Correspondence Address:
Swapnil J Paralikar
18, Taksh Bungalows, Near Shobhana Nagar, Vasna Road, Baroda 390 021, Gujarat
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0019-5278.107066
High altitude pulmonary edema (HAPE) is a noncardiogenic pulmonary edema which typically occurs in lowlanders who ascend rapidly to altitudes greater than 2500-3000 m. Early symptoms of HAPE include a nonproductive cough, dyspnoea on exertion and reduced exercise performance. Later, dyspnoea occurs at rest. Clinical features are cyanosis, tachycardia, tachypnoea and elevated body temperature generally not exceeding 38.5°C. Rales are discrete initially and located over the middle lung fields. HAPE mainly occurs due to exaggerated hypoxic pulmonary vasoconstriction and elevated pulmonary artery pressure. It has been observed that HAPE is a high permeability type of edema occurring also due to leaks in the capillary wall ('stress failure'). Slow descent is the most effective method for prevention; in addition, graded ascent and time for acclimatization, low sleeping altitudes, avoidance of alcohol and sleeping pills, and avoidance of exercise are the key to preventing HAPE. Treatment of HAPE consists of immediate improvement of oxygenation either by supplemental oxygen, hyperbaric treatment, or by rapid descent.
Keywords: High altitude, high altitude pulmonary edema, hypoxic pulmonary vasoconstriction
How to cite this article:
Paralikar SJ. High altitude pulmonary edema-clinical features, pathophysiology, prevention and treatment. Indian J Occup Environ Med 2012;16:59-62 |
How to cite this URL:
Paralikar SJ. High altitude pulmonary edema-clinical features, pathophysiology, prevention and treatment. Indian J Occup Environ Med [serial online] 2012 [cited 2022 Aug 9];16:59-62. Available from: https://www.ijoem.com/text.asp?2012/16/2/59/107066 |
| Introduction | |  |
Sojourns to high altitude are common for adventure and recreational purposes. Too rapid an ascent or inability to acclimatize leads to high altitude illnesses. These include acute mountain sickness (AMS), high altitude cerebral edema (HACE) and high altitude pulmonary edema (HAPE).
The most common cause of death related to high altitude, HAPE is completely and easily reversed if recognized early and treated properly. HAPE is a non-cardiogenic pulmonary edema which occurs in two forms. The first form typically occurs in un-acclimatized lowlanders who ascend rapidly to altitudes greater than 2500-3000 m. The second form, also called re-entry HAPE, occurs in high landers returning after a sojourn at a lower altitude. The two forms very probably share the same pathophysiology. This article discusses the pathophysiological mechanisms responsible for HAPE and elaborates on various modalities for its prevention and treatment.
| History of High Altitude Pulmonary Edema | | |
HAPE was misdiagnosed for centuries, as evidenced by frequent reports of young, vigorous men suddenly dying of "pneumonia" within days of arriving at high altitude. The death of Dr. Jacottet, "a robust, broad-shouldered young man," on Mont Blanc in 1891 (he refused descent so that he could "observe the acclimatization process" in himself) may have provided the first autopsy report of HAPE. Angelo Mosso wrote, "From Dr. Wizard's post-mortem examination…. the most immediate cause of death was therefore probably a suffocative catarrh accompanied by acute edema of the lungs…. I have gone into particulars of this sorrowful incident because a case of inflammation of the lungs also occurred during our expedition, on the summit of Monte Rossa, from which, however, the sufferer fortunately recovered."
On an expedition to K2 (Karakoram Range, Pakistan) in 1902, Alistair Crowley described a climber "suffering from edema of both the lungs and his mind was gone." [1] In the Andes, physicians were familiar with pulmonary edema peculiar to high altitude, but the English speaking world was largely oblivious to the phenomenon. This changed in 1960 when Charles Houston, an Aspen internist, reported on a healthy 21-year old cross country skier who developed pulmonary edema while crossing a 3,650-meter pass. His chest radiograph showed pulmonary edema, while his electrocardiogram displayed nonspecific changes. Although such cases had been termed "high altitude pneumonia", Houston recognized this to be acute pulmonary edema without heart disease. Houston's series of four patients included a 26-year old physician who undertook a self-examination with a sthethoscope and could detect fine, moist rales. [2] Hultgren performed cardiac catheterization on seven patients with HAPE at the Chulec General Hospital in Peru. The patients had pulmonary hypertension, reduced cardiac outputs, and low pulmonary artery occlusion pressure. [3] The large of number of Indian troops stationed in the Himalayas provided further for description of HAPE in otherwise young healthy men. [4],[5] Since then, many studies and reviews have been published and HAPE is still the subject of intense investigation.
| Epidemiology | | |
The estimated incidence of HAPE in visitors to ski resorts in the Rocky Mountains of Colorado is 0.01-0.1%. [6] In a general alpine mountaineering population, the prevalence of HAPE is <0.2%. [7] The HAPE incidence among trekkers in the Himalayas and climbers in the Alps ascending at a rate > 600m/day is around 4%. [8],[9] In an unselected population of Indian soldiers, airlift to an altitude of 5500m was associated with a HAPE incidence of up to 15%. [10]
| Clinical Features | | |
HAPE presents within 2-5 days of arrival at high altitude. It is rarely observed below altitudes of 2500-3000 m and after 1 week of acclimatsation at a particular altitude.
In most cases, it is preceded by symptoms of acute mountain sickness. Early symptoms of HAPE include a subtle nonproductive cough, dyspnoea on exertion and reduced exercise performance. As HAPE progresses, cough worsens and the subject may have a debilitating degree of dyspnoea, even at rest. Orthopnea may occur. Gurgling in the chest and pink frothy sputum indicate advanced cases. The clinical features are cyanosis, tachypnoea, tachycardia and elevated body temperature generally not exceeding 38.5°C. Rales are discrete initially and located over the middle lung fields. Imaging of the thorax reveals patchy opacities with inconsistent predominance of location, but often infiltrates are seen in the region of the right middle lobe [Figure 1]. [11],[12]
Subclinical HAPE probably occurs and causes no or minimal symptoms which can be ignored or attributed to other factors. The true incidence is unknown, but two recent studies have suggested that upwards of 50% of persons may have subclinical fluid accumulation in the lungs, consistent with occult edema which resolves spontaneously even though subjects remain at high altitude. [13],[14]
| Pathophysiology | | |
Exaggerated hypoxic pulmonary vasoconstriction and pulmonary hypertension
In contrast to systemic blood vessels which dilate in response to hypoxia, pulmonary blood vessels constrict. This constriction in non-homogenous, probably reflecting the distribution of smooth muscle in the walls of the arteries. [15] This response of the smooth muscle cells in the pulmonary vasculature begins within seconds and involves inhibition of voltage-dependent potassium channels, membrane depolarization and calcium entry through L-type calcium channels. Moreoever, hypoxia up-regulates transient receptor potential channels, leading to calcium entry through receptor and store-operated channels. [16]
Exaggerated hypoxic pulmonary vasoconstriction (HPV) can be attributed to increased susceptibility of the pulmonary vasculature-to sympathetic activity and/or high levels of endothelin-1. In addition, the endothelium mediated vasodilator response is blunted. This has been demonstrated by observing the response to acetylcholine in hypoxia measured by an impaired venous occlusion plethysmography in HAPE susceptible vs. non-susceptible controls. [17] Morevoever, upon acute exposure to hypoxia, exhaled nitric oxide concentrations and nitrite/nitrate in the BAL fluid tend to decrease in individuals prone to HAPE, whereas they increase in those resistant to the condition. [18],[19],[20] Also in susceptible individuals the prophylactic intake of tadalafil, a phosphodiesterase-5 inhibitor, prevents high altitude pulmonary hypertension and HAPE. [21]
Mechanisms accounting for increased capillary pressure and pulmonary capillary hypertension
There are at least two mechanisms responsible for the occurrence of pulmonary hypertension. The first is inhomogenous pulmonary vasoconstriction causing regional overperfusion of capillaries in areas of low arterial vasoconstriction. [11]
The second is hypoxic constriction occurring at the level of the pulmonary veins, increasing the resistance downstream of the region of fluid filtration. [22]
High permeability type of edema- 'stress failure' of the pulmonary capillaries
Broncho-alveolar lavage (BAL) performed in HAPE-susceptible adults within a day after ascent to 4559 m revealed elevated red blood cell counts and serum derived protein concentrations in BAL fluid. [18] However, the number of alveolar macrophages/ul and neutrophils/ul and the concentration of pro-inflammatory mediators interleukin-1(IL-1), TNF-α, IL-8, thromboxane, prostaglandin E 2 , and leukotriene B 4 (LTB 4 ), was not increased. These results are consistent with studies done by West and colleagues [23] in rabbit lungs that showed that a rapid exposure of the pulmonary microcirculation to transvascular pressures of 40-60 cm H 2 O (30-44 mmHg) within 1 min is a hydraulic stress that exceeds the load bearing limits of the membrane collagen network and results in ruptures of the basement membrane and thus the alveolar-capillary barrier. [23],[24] West had coined the structural engineering term 'stress failure' for this phenomenon.
In conclusion, the results of these studies indicate that HAPE is a hydrostatic type of pulmonary edema, the pathophysiological mechanism of which is excessive hypoxic pulmonary vasoconstriction of small arteries and veins, probably leading to over distension of the vessel wall, which opens the cellular junctions and possibly causes stress failure of the alveolo-capillary membrane. [11]
Reduced fluid clearance from the alveolar space
A further mechanism that may contribute to the pathophysiology of HAPE is a diminished capacity for alveolar fluid reabsorption. Removal of alveolar fluid is driven by the active reabsorption of Na + that enters the cells via Na channels and Na-coupled transport (Na/X) and is extruded by Na + K + ATPases. Thus active Na reabsorption generates the osmotic gradient for the reabsorption of water. Results obtained in cultured alveolar epithelial cells and hypoxia-exposed rats shows that hypoxia:
- Inhibits the activity and expression of various Na transporters, the most important being apical membrane epithelial Na channels and basolateral Na + K + ATPase
- Decreases transepithelial Na transport
- Decreases the reabsorption of fluid instilled into the lung.
Taken together, these findings suggest that impaired clearance of fluid filtered into the alveoli may be involved in the pathophysiology of HAPE. [25]
| Prevention | | |
Slow ascent is the most effective method of prevention, and one that is effective even in susceptible individuals. Apart from graded ascent and time for acclimatization, low sleeping altitudes, avoidance of alcohol and sleeping pills, and avoidance of exercise, are the key to preventing HAPE. Since exercise-induced circulatory changes may worsen or cause pulmonary edema, vigorous exercise should be avoided during the first days of altitude exposure by individuals with a history of HAPE. [1],[11]
Research over the previous two decades has focused on mechanisms responsible for HAPE, and have centred primarily on the fact that accentuated pulmonary hypertension on ascent contributes to the development of HAPE. Bartsch et al. took this physiologic observation and tested the hypothesis that minimizing the pulmonary hypertension would prevent HAPE. They used a calcium channel blocker, nifedipine, in HAPE-s subjects on rapid ascent to 4559 m and essentially prevented HAPE. This study was considered an important link between clinical and physiological observations and therapeutic tools. [26] Hence, prophylaxis with nifedipine can be recommended in individuals with a history of unquestionable HAPE if slow ascent is not possible. 60 mg daily of a slow-release formulation should be given, starting with the ascent and ending on the third or fourth day after arrival at the final altitude, if the stay is to be prolonged, or after returning to an altitude below 3000 m or one to which the individual is acclimatized. It should be emphasized that nifedipine prevents HAPE, but is not effective for the treatment of acute mountain sickness. [11]
Acetazolamide is a carbonic anhydrase inhibitor and is effective in acute mountain sickness (AMS). It blunts hypoxic vasoconstriction in animals by its effect on calcium channels, [27],[28] but further research is needed to determine its efficacy in HAPE.
Given the uncertainties with regard to the preventive effect of inhaled beta-2-receptor agonists, these drugs are not recommended for the prophylaxis of HAPE. [11]
According to preliminary data, glucocorticoids have been found to be effective in preventing HAPE in susceptible adults when taken one day prior to ascent and continued during ascent and stay at 4559 m. Glucocorticoids may be effective by stimulation of cGMP production in hypoxia, increasing in the activity of nitric oxide synthase and by increasing the activity of the epithelial Na + K + AT Pase pump. Although prophylaxis with dexamethasone for individuals susceptible to HAPE and AMS appears attractive, before general recommendation can be given further studies are needed to determine the minimal effective dose, its best route of administration (topical vs. systemic) and its safety profile in the setting of mountaineering. [11],[12]
| Treatment | | |
Immediate improvement of oxygenation either by supplemental oxygen, hyperbaric treatment, or by rapid descent is the treatment of choice for HAPE. For the mountaineer in a remote area without medical care, descent has first priority, while the tourist with HAPE visiting a high altitude plateau in the Andes, Himalayas, or Rocky Mountains may stay at altitude if medical facilities are available. If it takes few days in a remote area to reach lower altitude, treatment with nifedipine is strongly recommended. [22] In mountaineers with HAPE at 4559 m, treatment with 20mg slow-release nifedipine taken every six hours led to a persistent relief of symptoms, improvement of gas exchange, and radiographic clearance over an observational period of 34 h. In this study, nifedipine therapy was not associated with hypotension. [29] To date, there are no clinical trials on the use of more selective pulmonary vasodilators such as sildenafil or other phosphodiesterase-5 inhibitors in this setting.
In an area where medical infrastructure and assistance are available, vasodilatory treatment is not strictly necessary because with bed-rest and supplemental oxygen for 24 to 48 hrs, relief of symptoms is achieved within hours and complete clinical recovery within several days while staying at the same altitude. [22]
| References | | |
| 1. | Auerbach PS. Wilderness Medicine. 5 th ed. Philadelphia: Mosby Elsevier; 2007. 
|
| 2. | Houston CS. Acute pulmonary edema of high altitude. N Engl J Med 1960;263:478-80.
|
| 3. | Hultgren H, Spickard W: Medical experiences in Peru. Stanford Med Bull 1960;18:76-95.
|
| 4. | Singh I, Kapila CC, Khanna PK, Nanada RB, Rao BD. High-altitude pulmonary edema. Lancet 1965;191:229-34.
|
| 5. | Menon ND. High altitude pulmonary edema: A clinical study. N Engl J Med 1965;273:66-73.
|
| 6. | Sopocles Jr AM. High altitude pulmonary edema in Vail, Colorado, 1975-82. High Alt Med Biol 1986;144:569-73.
|
| 7. | Hochstrasser J, Nanzer A, Oelz O. Altitude edema in the Swiss Alps. Observations on the incidence and clinical course in 50 patients 1980-84. Schweiz Med Wochenschr 1986;116:866-73.
|
| 8. | Maggiorini M, Buhler B, Walter M, Oelz O. Prevalence of acute mountain sickness in the Swiss Alps. BMJ 1990;301:853-5.
|
| 9. | Hackett PH, Rennie D. Rales, peripheral edema, retinal haemorrhage and acute mountain sickness. Am J Med 1979;67:214-8.
|
| 10. | Singh I, Roy SB. High altitude pulmonary edema: Clinical, hemodynamic, and pathologic studies. In: Command UA, Ra D, editors. Biomedicine of high terrestrial elevation problems. Washington D.C.; 1969. p. 108-20.
|
| 11. | Bartsch P, Mairbauri H, Swenson ER, Maggiorini M. High altitude pulmonary edema. Swiss Med Wkly 2003;133:377-84.
|
| 12. | Schoene RB. Illnesses at high altitude. Chest 2008;134:402-16.
|
| 13. | Cremona G, Asnaghi R, Baderna P, Brunetto A, Brutsaert T, Cavallaro C, et al. Pulmonary extravascular fluid accumulation in recreational climbers: A prospective study. Lancet 2002;359:303-9.
|
| 14. | Mason NP, Petersen M, Melot C, Imanov B, Matveykine O, Gautier MT, et al. Serial changes in nasal potential difference and lung electrical impedance tomography at high altitude. J Appl Physiol 2003;94:2043-50.
|
| 15. | Barrett KE, Barman SM, Boitano S, Brooks HL: Ganong's Review of Medical Physiology, 23 rd ed. New Delhi: Tata-McGraw-Hill; 2009. p. 619-20.
|
| 16. | Murray F, Insel PA, Yuan IX. Role of O (2)-sensitive K(+) and Ca (2+) channels in the regulation of pulmonary circulation: Potential role of caveolae and implications for high altitude pulmonary edema. Respir Physiol Neurobiol 2006;151:192-208.
|
| 17. | Beall CM, Laskowski D, Strohl KP, Soria R, Villena M, Vargas E, et al. Pulmonary nitric oxide in mountain dwellers. Nature 2001;414:411-2.
|
| 18. | Swenson S, Maggiorini M, Mongovin S, Gibbs S, Greve I, Mairbauri H, et al. High altitude pulmonary edema is a non-inflammatory high permeability leak of the alveolar-capillary barrier. JAMA 2002;287:226-35.
|
| 19. | Duplain H, Sartori C, Lepori M, Figli M, Allemann Y, Nicod P, et al. Exhaled nitric oxide in high-altitude pulmonary edema: Role in the regulation of pulmonary vascular tone and evidence for a role against inflammation. Am J Respir Crit Care Med 2000;162:221-4.
|
| 20. | Busch T, Bartsch P, Pappert D, Grunig E, Hildebrandt W, Elser H, et al. Hypoxia decreases exhaled nitric oxide in mountaineers susceptible to high-altitude pulmonary edema. Am J Respir Crit Care Med 2001;163:368-73.
|
| 21. | Maggiorini M, Brunner-La Rocca HP, Bartsch P, Fischler M, Bohm T, Bloch KE, et al. Dexamethasone and tadalafil prophylaxis prevents both excessive pulmonary constriction and high altitude pulmonary edema in susceptible subjects. Eur Respir J 2004; 24(Suppl 28):S110.
|
| 22. | Maggiorini M. High altitude-induced pulmonary edema. Cardiovasc Res 2006;72:41-50.
|
| 23. | West JB, Tsukimoto K, Mathieu -Costello O, Prediletto R. Stress failure in pulmonary capillaries. J Appl Physiol 1991;70:1731-42.
|
| 24. | West JB, Mathieu-Costello O, Jones JH, Birks EK, Logemann RB, Pascoe JR, et al. Stress failure of pulmonary capillaries in racehorses with exercise-induced pulmonary haemorrhage. J Appl Physiol 1993;75:1097-109.
|
| 25. | Bartsch P, Mairbauri H, Maggiorini M, Swenson ER. Physiological aspects of high-altitude pulmonary edema. J Appl Physiol 2005;98:1101-110.
|
| 26. | Bartsch P, Maggiorini M, Ritter M, Noti C, Vock P, Oelz O. Prevention of high-altitude pulmonary edema by nifedipine. N Engl J Med 1991;325:1306-7.
|
| 27. | Swenson ER. Carbonic anhydrase inhibitors and ventilation: A complex interplay of stimulation and suppression. Eur Resp J 1998;12:1242-7.
|
| 28. | Deem S, Hedges R, Ker M, Swenson ER. Acetazolamide reduces the rate and magnitude of hypoxic pulmonary vasoconstriction in isolated perfused rabbit lung. Respir Physiol 2000;123:109-19.
|
| 29. | Oelz O, Maggiorini M, Ritter M, Waber U, Jenni R, Vock P, et al. Nifedipine for high altitude pulmonary edema. Lancet 1989;2:1241-4.
|
[Figure 1]
| This article has been cited by | | 1 |
Endogenous humoral determinants of vascular endothelial dysfunction as triggers of acute poisoning complications |
|
| Jury Ju. Ivnitsky, Timur V. Schäfer, Vladimir L. Rejniuk, Alexandr I. Golovko | | Journal of Applied Toxicology. 2022; | | [Pubmed] | [DOI] | | | 2 |
Preliminary Evidence-Based Method of Medical Kit Design for Wilderness Expeditions Modeled by a High-Altitude Expedition to Mount Kilimanjaro |
|
| Thomas D. Wagner, Megan Paul, Connor A. Tukel, Benjamin Easter, Dana R. Levin | | The Journal of Emergency Medicine. 2022; | | [Pubmed] | [DOI] | | | 3 |
Studies on Metabolic Alterations due to Hypobaric Hypoxia in Serum using NMR Spectroscopy |
|
| Sunil Koundal, Sonia Gandhi, Subash Khushu | | Biomarkers. 2022; : 1 | | [Pubmed] | [DOI] | | | 4 |
Association of variants m.T16172C and m.T16519C in whole mtDNA sequences with high altitude pulmonary edema in Han Chinese lowlanders |
|
| Yan Wang, Xuewen Huang, Fujun Peng, Huiling Han, Yanan Gu, Xin Liu, Zhichun Feng | | BMC Pulmonary Medicine. 2022; 22(1) | | [Pubmed] | [DOI] | | | 5 |
Role of point-of-care ultrasound in grading the severity and early diagnosis of high-altitude pulmonary edema at a peripheral hospital |
|
| Saurabh Sud, Yogesh Kumar, Saurabh Bharadwaj, Deepak Dwivedi, Arun Kumar, Archit Garg | | Journal of Marine Medical Society. 2022; 0(0): 0 | | [Pubmed] | [DOI] | | | 6 |
Quercetin: a savior of alveolar barrier integrity under hypoxic microenvironment |
|
| Ankit Tripathi, Puja P. Hazari, Anil K. Mishra, Bhuvnesh Kumar, Sarada S.K. Sagi | | Tissue Barriers. 2021; 9(2): 1883963 | | [Pubmed] | [DOI] | | | 7 |
Evaluation of Serial Chest Radiographs of High-Altitude Pulmonary Edema Requiring Medical Evacuation from South Pole Station, Antarctica: From Diagnosis to Recovery |
|
| Craig D Nowadly, Alex J Solomon, Sean M Burke, John S Rose | | Military Medicine. 2021; 186(11-12): e1135 | | [Pubmed] | [DOI] | | | 8 |
Hypoxia-mediated alterations in pulmonary surfactant protein expressions: Beneficial effects of quercetin prophylaxis |
|
| Ankit Tripathi, Bhuvnesh Kumar, Sarada S.K. Sagi | | Respiratory Physiology & Neurobiology. 2021; 291: 103695 | | [Pubmed] | [DOI] | | | 9 |
Evaluation of High Altitude Interstitial Pulmonary Edema in Healthy Participants Using Rapid 4-View Lung Ultrasound Protocol During Staged Ascent to Everest Base Camp |
|
| Craig D. Nowadly, Kenneth M. Kelley, Desiree H. Crane, John S. Rose | | Wilderness & Environmental Medicine. 2021; 32(3): 278 | | [Pubmed] | [DOI] | | | 10 |
Characteristics of High Altitude Pulmonary Edema in Naqu at the Altitude of 4500 m |
|
| Jiahuan Xu, Lianggang Lv, Bo He, Guoqiang Wang, Bianbazhuoma, Delei Kong | | The American Journal of the Medical Sciences. 2021; 362(2): 154 | | [Pubmed] | [DOI] | | | 11 |
Long Non-coding RNA LINC-PINT and LINC00599 Polymorphisms are Associated With High-altitude Pulmonary Edema in Chinese |
|
| Xue He, Jianwen Zheng, Yongjun He, Yuhe Wang, Li Wang, Mei Bai, Tianbo Jin, Dongya Yuan | | Archivos de Bronconeumología (English Edition). 2020; 56(6): 360 | | [Pubmed] | [DOI] | | | 12 |
Long Non-coding RNA LINC-PINT and LINC00599 Polymorphisms are Associated With High-altitude Pulmonary Edema in Chinese |
|
| Xue He, Jianwen Zheng, Yongjun He, Yuhe Wang, Li Wang, Mei Bai, Tianbo Jin, Dongya Yuan | | Archivos de Bronconeumología. 2020; 56(6): 360 | | [Pubmed] | [DOI] | | | 13 |
Ein Fall aus der Höhenmedizin |
|
| S. Stuppner, A. Ruiu, E. Stirpe, L. Bonazza | | Der Radiologe. 2020; 60(3): 269 | | [Pubmed] | [DOI] | | | 14 |
Subclinical elevated B-type Natriuretic Peptide (BNP) indicates endothelial dysfunction contributing to hypoxia susceptibility in healthy individuals |
|
| Rahul Khatri, Rajinder K. Gupta, Praveen Vats, Vishal Bansal, Anand Kumar Yadav, Prasanna K. Reddy, Abhishek Bharadwaj, Pooja Chaudhary, Shivani Sharma, Amir Chand Bajaj, Padma Deskit, Deepak Dass, Thiruthara P. Baburaj, Shashi Bala Singh, Bhuvnesh Kumar | | Life Sciences. 2020; 260: 118408 | | [Pubmed] | [DOI] | | | 15 |
Deregulated hypoxic response in myeloid cells: A model for high-altitude pulmonary oedema (HAPE) |
|
| Milos Gojkovic, Gabriella S. Darmasaputra, Pedro Veliça, Helene Rundqvist, Randall S. Johnson | | Acta Physiologica. 2020; 229(2) | | [Pubmed] | [DOI] | | | 16 |
Association between CYP2C19 gene polymorphisms and susceptibility to high-altitude pulmonary edema |
|
| Xue He, Mei Bai, Xiwen Guan, Jianwen Zheng, Yongjun He, Dongya Yuan, Tianbo Jin, Li Wang | | The Clinical Respiratory Journal. 2020; 14(10): 973 | | [Pubmed] | [DOI] | | | 17 |
Acute Lung Edema as a Presentation of Severe Acute Reentry High-Altitude Illness in a Pediatric Patient |
|
| Alfredo Merino-Luna, Julio Vizcarra-Anaya | | Case Reports in Pediatrics. 2020; 2020: 1 | | [Pubmed] | [DOI] | | | 18 |
Changes in corneal thickness in patients with high-altitude pulmonary edema after systemic oxygen therapy |
|
| Sagarika Patyal, ArunKumar Yadav, Atul Kotwal | | Indian Journal of Ophthalmology. 2018; 66(11): 1554 | | [Pubmed] | [DOI] | | | 19 |
Angiotensin II receptor 1 gene variants are associated with high-altitude pulmonary edema risk |
|
| Tianbo Jin, Yongchao Ren, Xikai Zhu, Xun Li, Yongri Ouyang, Xue He, Zhiying Zhang, Yuan Zhang, Longli Kang, Dongya Yuan | | Oncotarget. 2016; 7(47): 77117 | | [Pubmed] | [DOI] | | | 20 |
Diffuse Alveolar Hemorrhage from Systemic Lupus Erythematosus Misdiagnosed as High Altitude Pulmonary Edema |
|
| Suzhi Li,Yuliang Wang,Xuewen Huang,Jingxin Cao,Dingzhou Yang | | High Altitude Medicine & Biology. 2015; 16(1): 67 | | [Pubmed] | [DOI] | | | 21 |
High altitude pulmonary edema in mountain climbers |
|
| Krzysztof Korzeniewski,Aneta Nitsch-Osuch,Aneta Guzek,Dariusz Juszczak | | Respiratory Physiology & Neurobiology. 2014; | | [Pubmed] | [DOI] | | | 22 |
Effects of early mechanical ventilation on oxygenation and hemodynamics in acute high altitude pulmonary edema patients complicated by acute respiratory distress syndrome |
|
| Shi, Z.-S., Ma, S.-Q., Chen, Q., He, Z.-Z. | | Chinese Critical Care Medicine. 2013; 25(10): 618-621 | | [Pubmed] | |
|
|
|
|
|
|
|
|
